Drug profile · INN
darifenacin hydrobromide
EMSELEX
darifenacin hydrobromide (EMSELEX) is a muscarinic acetylcholine receptor m3 antagonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — darifenacin hydrobromide
- US status
- approved
- Class
- Genito-urinary system and sex hormones (G04)
- Route
- ORAL
- Patents
- 1
- Programs
- 0
- Data quality
- 0.84
Quick answer
darifenacin hydrobromide (EMSELEX) is a muscarinic acetylcholine receptor m3 antagonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Muscarinic acetylcholine receptor M3 antagonist
Primary target: Muscarinic acetylcholine receptor M2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Related & competitor drugs
Related patents
Frequently asked questions
What is darifenacin hydrobromide?
darifenacin hydrobromide (EMSELEX) is a muscarinic acetylcholine receptor m3 antagonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for darifenacin hydrobromide?
EMSELEX is a marketed brand name for darifenacin hydrobromide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of darifenacin hydrobromide?
darifenacin hydrobromide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.